New Delhi, Dec 6 (PTI) Biotechnology major Biocon on Saturday said it will fully integrate Biocon Biologics with itself, in a deal valuing the biologics unit at USD 5.5 billion.

As part of the transaction, Biocon will acquire the remaining stake in Biocon Biologics Ltd from Serum Institute Life Sciences, Tata Capital Growth Fund II and Activ Pine LLP through a share swap, valuing Biocon Biologics at USD 5.5 billion, the Bengaluru-based company said in a regulatory filing.

The share-swap ratio has been fixed at 70.28 Biocon shares for every 100 Biocon Biologics shares, at a share price of Rs 405.78 per Biocon share, it added.

Further, Biocon will acquire the residual stake held by Mylan Inc (Viatris) for a total consideration of USD 815 million, of which USD 400 million will be payable i

See Full Page